Most Glucosamine/Chondroitin Supplements Pass Content, Dosage Tests – CR
This article was originally published in The Tan Sheet
Executive Summary
Glucosamine/chondroitin supplement consumers should seek the least expensive combination products that contain at least 90% of the labeled amount of the ingredients, Consumer Reports advises in its upcoming January issue
You may also be interested in...
ANA writes to Consumer Reports
American Nutraceutical Association disputes Consumer Reports advice that consumers try least expensive chondroitin/glucosamine product meeting USP's 90% lower potency limit standard. Recommendation was conveyed in a review of joint health products published in magazine's January issue (1"The Tan Sheet" Dec. 17, 2001, p. 18). In a Jan. 24 letter, ANA contends review failed to mention bioavailability, citing a University of Maryland study which found many products that passed 90% potency test were not bioavailable. Without established bioavailability standards, ANA instead suggests consumers "find out which brand was used in [a successful study] and buy that"...
ANA writes to Consumer Reports
American Nutraceutical Association disputes Consumer Reports advice that consumers try least expensive chondroitin/glucosamine product meeting USP's 90% lower potency limit standard. Recommendation was conveyed in a review of joint health products published in magazine's January issue (1"The Tan Sheet" Dec. 17, 2001, p. 18). In a Jan. 24 letter, ANA contends review failed to mention bioavailability, citing a University of Maryland study which found many products that passed 90% potency test were not bioavailable. Without established bioavailability standards, ANA instead suggests consumers "find out which brand was used in [a successful study] and buy that"...
ANA writes to Consumer Reports
American Nutraceutical Association disputes Consumer Reports advice that consumers try least expensive chondroitin/glucosamine product meeting USP's 90% lower potency limit standard. Recommendation was conveyed in a review of joint health products published in magazine's January issue (1"The Tan Sheet" Dec. 17, 2001, p. 18). In a Jan. 24 letter, ANA contends review failed to mention bioavailability, citing a University of Maryland study which found many products that passed 90% potency test were not bioavailable. Without established bioavailability standards, ANA instead suggests consumers "find out which brand was used in [a successful study] and buy that"...